Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 3/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.34 |
| ▸ | TLR4 | O00206 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 5/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9924936 | 0.96 | SMN1; SMN2 (0.35) | SMN1; SMN2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9924800 | 0.95 | SMN1; SMN2 (0.35) | SMN1; SMN2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19188385 | 0.95 | SMN1; SMN2 (0.35) | SMN1; SMN2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9924851 | 0.95 | SMN1; SMN2 (0.35) | SMN1; SMN2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9924930 | 0.94 | SCN9A (0.36) | SMN1; SMN2TLR4RIPK1ACACBSCN9A | |
| SCHEMBL9924929 | 0.94 | SCN9A (0.36) | SMN1; SMN2TLR4RIPK1ACACBSCN9A | |
| SCHEMBL9925018 | 0.94 | TLR4 (0.33) | SMN1; SMN2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9925088 | 0.94 | SMN1; SMN2 (0.35) | SMN1; SMN2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9925084 | 0.90 | ACACB (0.33) | SMN1; SMN2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9924935 | 0.90 | SCN9A (0.35) | SMN1; SMN2PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468707-B1 | DECAHYDRONAPHTHALENE COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS CONTAINING THE COMPOUNDS, AND LIQUID CRYSTAL DISPLAY DEVICES CONTAINING THE LIQUID CRYSTAL COMPOSITIONS | JNC CORP (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-8465674-B2 | Decahydronaphthalene compound, liquid crystal composition including the compound and liquid crystal display device containing the liquid crystal composition | JNC CORPORATION (JP) | 2013-06-18 | — | — | US | disclosed |
| US-8465674-B2 | Decahydronaphthalene compound, liquid crystal composition including the compound and liquid crystal display device containing the liquid crystal composition | JNC CORPORATION (JP) | 2013-06-18 | — | — | US | disclosed |
| EP-2468707-A1 | DECAHYDRONAPHTHALENE COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS CONTAINING THE COMPOUNDS, AND LIQUID CRYSTAL DISPLAY ELEMENTS CONTAINING THE LIQUID CRYSTAL COMPOSITIONS | JNC Corporation (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20120145959-A1 | DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION | JNC PETROCHEMICAL CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
| US-20120145959-A1 | DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION | JNC PETROCHEMICAL CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120145959-A1 | DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION | DCUN1D2, OCIAD1, CPNE4 | SMN1; SMN2 4294/4885PDE4A 3218/4885PDE4B 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.